Organization
Henry Ford Cancer Institute, Detroit, MI
21 abstracts
Abstract
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.Org: The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Henry Ford Cancer Institute, Detroit, MI, START San Antonio, San Antonio, TX, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, MUSC Hollings Cancer Center, Charleston, SC,
Abstract
Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.Org: Medical University of Gdańsk, Gdańsk, Poland, International Centre for Thoracic Cancers (CICT), Gustave Roussy Cancer Center, Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine,
Abstract
Race and decisional conflict about genetic testing in patients with advanced prostate cancer.Org: Henry Ford Hospital, Henry Ford Health System, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Henry Ford Cancer Institute, Detroit, MI,
Abstract
Patient-reported and clinical outcomes among patients with pancreatic cancer.Org: Henry Ford Hospital, Henry Ford Health System, Henry Ford Cancer Institute, Detroit, MI,
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, UPMC Hillman Cancer Center, NSABP Foundation, Inc. Pathology Lab,
Abstract
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).Org: Next Oncology Virginia and Virginia Cancer Specialists, Henry Ford Cancer Institute, Detroit, MI, UC Davis Comprehensive Cancer Center, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Henan Cancer Hospital,
Abstract
XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Summit Cancer Centers, Spokane Valley, WA, Virginia Cancer Specialists, Perlmutter Cancer Center at NYU Langone Health Medical Center,
Abstract
A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Stanford University School of Medicine, Palo Alto, CA, Henry Ford Cancer Institute, Detroit, MI,
Abstract
Characteristics and outcomes of patients with small cell lung cancer (SCLC) detected with CT screening at a single health system.Org: Henry Ford Cancer Institute, Detroit, MI, Henry Ford Health System, Detroit, MI, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, Henry Ford Hospital,
Abstract
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Henry Ford Cancer Institute, Detroit, MI, University of Colorado Denver Anschutz Medical Center, Dana-Farber Cancer Institute,
Abstract
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea,
Abstract
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alliance Statistics and Data Center, Mayo Clinic, University of North Carolina at Chapel Hill,
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.Org: University of Texas MD Anderson Cancer Center, The University of Pittsburgh, NRG Oncology SDMC, NSABP Foundation, Inc., UMPC Hillman Cancer Center,
Abstract
Lowering the bar for consideration of neoadjuvant chemotherapy in early-stage HER2-positive breast cancers.Org: Henry Ford Cancer Institute, Detroit, MI, Henry Ford Health System,
Abstract
Treatment pattern of early-stage premenopausal breast cancer patients with low Oncotype DX score: Single center experience.Org: Henry Ford Health System, Department of Hematology/Oncology, Detroit, MI, Henry Ford Hospital, Henry Ford Cancer Institute, Detroit, MI,
Abstract
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis.Org: The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, University of Colorado Cancer Center, Aurora, CO, USA, Henry Ford Cancer Institute, Detroit, MI, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN, START San Antonio, San Antonio, TX,
Abstract
The predictive value of CA-125 for radiologic evidence of metastatic disease in type 2 endometrial cancers.Org: Henry Ford Health System, Henry Ford Cancer Institute, Detroit, MI,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,
Abstract
Prognostic relevance of 3q amplification (AMP) in a racially diverse patient population with advanced squamous cell carcinoma of the lung.Org: Henry Ford Health System, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, Henry Ford Hospital, Saint Joseph Mercy Health System, Henry Ford Cancer Institute, Detroit, MI,
Abstract
A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC).Org: University of Michigan, University of Michigan, Rogel Cancer Center, Henry Ford Cancer Institute, Detroit, MI, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, University of Michigan Health System Comprehensive Cancer Center,
Abstract
False positive PET scan in patients with treated malignancy following COVID-19 vaccination.Org: Henry Ford Cancer Institute, Detroit, MI, Henry Ford Health System, Merck & Co., Inc., Henry Ford Hospital,